Hikma Pharmaceuticals (LON:HIK) Trading Up 7.4% – Still a Buy?

Hikma Pharmaceuticals PLC (LON:HIK)’s stock price was up 7.4% on Friday . The stock traded as high as GBX 2,114 ($28.13) and last traded at GBX 2,084 ($27.73). Approximately 937,337 shares traded hands during mid-day trading, a decline of 32% from the average daily volume of 1,387,898 shares. The stock had previously closed at GBX 1,941 ($25.83).

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Berenberg Bank reaffirmed a “buy” rating and set a GBX 2,560 ($34.07) price objective on shares of Hikma Pharmaceuticals in a research report on Monday, March 10th. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Hikma Pharmaceuticals in a research report on Friday, March 7th.

Hikma Pharmaceuticals Stock Down 1.1%

The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.82. The company has a market cap of £5.72 billion, a price-to-earnings ratio of 20.23, a P/E/G ratio of 2.38 and a beta of 0.41. The stock has a fifty day moving average price of GBX 1,951.57 and a two-hundred day moving average price of GBX 2,014.56.

Hikma Pharmaceuticals Increases Dividend

The company also recently announced a dividend, which was paid on Thursday, May 1st. Stockholders of record on Thursday, March 20th were issued a dividend of $0.48 per share. The ex-dividend date was Thursday, March 20th. This represents a dividend yield of 1.8%. This is an increase from Hikma Pharmaceuticals’s previous dividend of $0.32. Hikma Pharmaceuticals’s dividend payout ratio (DPR) is currently 60.84%.

Insider Transactions at Hikma Pharmaceuticals

In related news, insider Victoria Hull sold 2,777 shares of the business’s stock in a transaction dated Tuesday, April 8th. The stock was sold at an average price of GBX 1,800 ($23.96), for a total value of £49,986 ($66,523.82). Insiders own 30.54% of the company’s stock.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.